Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882726 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 1
- Development phase
- 133
- Enrollment target
NCT00882726 is a Phase 1 study that has completed, run by Centocor. The registered enrollment target is 133 participants.
The verdict
NCT00882726, a Phase 1 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 133 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of CNTO 3649 following a single dose in healthy adults and following multiple doses in patients with Type 2 Diabetes Mellitus.
Interventions
- DRUG Placebo
- DRUG CNTO 3649 IV (Healthy participants)
- DRUG CNTO 3649 SC (Healthy participants)
- DRUG CNTO 3649 SC (Diabetic patients)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882726
The ClinicalTrials.gov registry entry for NCT00882726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00882726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00882726 about?
NCT00882726 is a clinical study titled "A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of CNTO 3649 following a single dose in healthy adults and following multiple doses in patients with Type 2 Diabetes Mellitus.
What is the current status of trial NCT00882726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 133 participants. The study started on 2009-02. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00882726?
The interventions under investigation include: Placebo (DRUG), CNTO 3649 IV (Healthy participants) (DRUG), CNTO 3649 SC (Healthy participants) (DRUG), CNTO 3649 SC (Diabetic patients) (DRUG).
Who is sponsoring clinical trial NCT00882726?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.